Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
New to investing? Check out these zero fee investment apps designed specifically for new investors to start building wealth.
28,005 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
JPMorgan's revised target to $134 underscores a brighter backdrop for Bunge as the Viterra deal closes and 2026 biofu...
Merlin's chief technology officer argues that autonomous systems could redefine aviation safety and national security...
CleanSpark stock surged after disclosing a $6.6 billion, 20-year data center lease in Georgia, underscoring a shift f...
Kick off your weekend with a focused set of 10 Sunday Reads for investors. This practical briefing translates headlin...
Ted Turner's launch of CNN and the dawn of nonstop coverage reshaped investing and budgeting for households. This pie...
Figure Technology Solutions agrees to purchase Kiavi for $717 million, expanding first-lien volume by about 40% and b...
When political rhetoric collides with market movement, investors feel the pull of headlines. This article breaks down...
Blackstone's flagship private-credit fund drew heavier redemptions than typical, underscoring strain in private credi...
Coinbase missed earnings and then endured a multi-hour outage tied to an AWS failure, shaking investors. bulls argue ...
President Trump asserts Europe freeloads on defense costs, triggering a global market response and renewed debates ov...
A new defense-focused ETF began trading in July 2026, joining VistaShares’ space and robotics funds as investors chas...